You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Zambon receives European Commission approval for Hopledo in Parkinson's disease

Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine

ReviR Therapeutics' RTX-117 receives FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth disease

Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic GEA eligible for ZIIHERA

Annovis Bio schedules corporate update webinar for next week

Cellenkos' CK0803 granted US FDA Fast Track designation for ALS

FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia

Labcorp to offer FDA-cleared pTau-217 blood test for Alzheimer's assessment

Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product

European Commission grants orphan designation for Vanda's imsidolimab

United Therapeutics wins FDA acceptance for ralinepag PAH filing

Acadia wins EU approval for DAYBU as first treatment for Rett syndrome

Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe

GSK's Jemperli wins FDA priority review for advanced rectal cancer

European Commission grants orphan designation for Lundbeck's asedebart

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026